Schizophrenia Research
Volume 119, Issue 1 , Pages 47-51 , June 2010

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

  • Ripu D. Jindal

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • University of Ottawa School of Medicine, Ottawa, Canada
    • Corresponding Author InformationCorresponding author. 3811 O'Hara Street, Pittsburgh, Pennsylvania, 15213 USA. Tel.: +1 412 512 9516.
    • ,
  • Anil K. Pillai

      Affiliations

    • Medical College of Georgia, Augusta, GA, USA
    • ,
  • Sahebrao P. Mahadik

      Affiliations

    • Medical College of Georgia, Augusta, GA, USA
    • ,
  • Kevin Eklund

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • ,
  • Debra M. Montrose

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • ,
  • Matcheri S. Keshavan

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Received 4 November 2009 ,Revised 23 December 2009 ,Accepted 30 December 2009.

References 

  1. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389:856–860
  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). 4th ed. Washington, DC: American Psychiatric Press; 1994;
  3. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: IA: University of Iowa; 1983;
  4. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: IA: University of Iowa; 1984;
  5. Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 2005;15:311–317
  6. Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 2000;60:783–794
  7. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003;71:127–131
  8. Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog. Neurobiol. 2005;76:99–125
  9. Buckley PF, Mahadik S, Pillai A, Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007;94:1–11
  10. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 2007;91:1–5
  11. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol. Psychiatry. 2006;59:812–815
  12. Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br. J. Pharmacol. 2008;153(Suppl 1):S310–S324
  13. Chen, D.C., Wang, J., Wang, B., Yang, S.C., Zhang, C.X., Zheng, Y.L., Li, Y.L., Wang, N., Yang, K.B., Xiu, M.H., Kosten, T.R., Zhang, X.Y., 2009. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) (2009 Sep 29).
  14. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001;52:79–86
  15. Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 1997;7:701–707
  16. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000;14:1–21
  17. First MD, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I disorders — patient edition. New York: Biometrics Research Department, NYSPI; 1995;
  18. Fisher M, Holland C, Merzenich MM, Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry. 2009;166:805–811
  19. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 2000;57:65–73
  20. Grassi-Oliveira R, Stein LM, Lopes RP, Teixeira AL, Bauer ME. Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression—a preliminary report. Biol. Psychiatry. 2008;64:281–285
  21. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatr. Res. 2007;41:31–35
  22. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 2001;411:86–89
  23. Guzman-Marin R, Ying Z, Suntsova N, Methippara M, Bashir T, Szymusiak R, et al. Suppression of hippocampal plasticity-related gene expression by sleep deprivation in rats. J. Physiol. 2006;575:807–819
  24. Hall H, Lawyer G, Sillen A, Jonsson EG, Agartz I, Terenius L, et al. Potential genetic variants in schizophrenia: a Bayesian analysis. World J. Biol. Psychiatry. 2007;8:12–22
  25. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003;23:6690–6694
  26. Hill JJ, Kolluri N, Hashimoto T, Wu Q, Sampson AR, Monteggia LM, et al. Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor. Biol. Psychiatry. 2005;57:932–934
  27. Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev. Neurother. 2008;8:1101–1113
  28. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 2002;328:261–264
  29. Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J. Psychiatr. Res. 1999;33:513–521
  30. Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, et al. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov. Today. 2009;14:690–697
  31. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol. Psychiatry. 2007;62:530–535
  32. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996;19:289–317
  33. Maisonpierre PC, Le Beau MM, Espinosa R, Ip NY, Belluscio L, de la Monte SM, et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics. 1991;10:558–568
  34. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N. Y. Acad. Sci. 2008;1144:97–112
  35. Mu JS, Li WP, Yao ZB, Zhou XF. Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res. 1999;835:259–265
  36. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001;63:71–124
  37. Ozan E, Okur H, Eker C, Eker OD, Gönül AS, Akarsu N. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res. Bull. 2010;81(1):61–65
  38. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology. 1998;37:1553–1561
  39. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 2003;60:117–123
  40. Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron. 1996;16:1137–1145
  41. Piccinni A, Marazziti D, Del Debbio A, Bianchi C, Roncaglia I, Mannari C, et al. Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol. Int. 2008;25:819–826
  42. Poo MM. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001;2:24–32
  43. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:1308–1311
  44. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry. 2009;42:270–276
  45. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 1999;45(1):17–25
  46. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry. 2008;64:527–532
  47. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 2005;15:319–329
  48. Shugart YY, Chen L, Day IN, Lewis SJ, Timpson NJ, Yuan W, et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur. J. Hum. Genet. 2009;17:1050–1055
  49. Stern AJ, Savostyanova AA, Goldman A, Barnett AS, van der Veen JW, Callicott JH, et al. Impact of the brain-derived neurotrophic factor Val66Met polymorphism on levels of hippocampal N-acetyl-aspartate assessed by magnetic resonance spectroscopic imaging at 3 Tesla. Biol. Psychiatry. 2008;64:856–862
  50. Thoenen H. Neurotrophins and neuronal plasticity. Science. 1995;270:593–598
  51. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol. Psychiatry. 2009;66:549–553
  52. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry. 2003;8:592–610
  53. Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry. 2005;10:637–650
  54. Wong J, Webster MJ, Cassano H, Weickert CS. Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex. Eur. J. NeuroSci. 2009;29:1311–1322

PII: S0920-9964(10)00002-2

doi: 10.1016/j.schres.2009.12.035

Schizophrenia Research
Volume 119, Issue 1 , Pages 47-51 , June 2010

Article Tools

* Image Usage & Resolution